Safety and Recommended Phase II Dose (RP2D) of the Selective Oral MEK1/2 Inhibitor Pimasertib (MSC1936369B/AS703026): Results of a Phase I Trial

A. Awada; J. P. Delord; N. Houede; C. Lebbe; T. Lesimple; J. H. M. Schellens; S. Rottey; R. Kefford; N. Rejeb; E. Raymond

doi:10.1016/S0959-8049(12)72401-2

Safety and Recommended Phase II Dose (RP2D) of the Selective Oral MEK1/2 Inhibitor Pimasertib (MSC1936369B/AS703026): Results of a Phase I Trial

A. Awada, J. P. Delord, N. Houede, C. Lebbe, T. Lesimple, J. H. M. Schellens, S. Rottey, R. Kefford, N. Rejeb, E. Raymond

Research output: Contribution to journal › Meeting abstract › peer-review

Original language	English
Article number	604
Pages (from-to)	185-186
Number of pages	2
Journal	European Journal of Cancer
Volume	48
DOIs	https://doi.org/10.1016/S0959-8049(12)72401-2
Publication status	Published - Nov 2012
Externally published	Yes
Event	24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - Dublin, Ireland Duration: 6 Nov 2012 → 9 Nov 2012

Access to Document

10.1016/S0959-8049(12)72401-2

Cite this

Awada, A., Delord, J. P., Houede, N., Lebbe, C., Lesimple, T., Schellens, J. H. M., Rottey, S., Kefford, R., Rejeb, N., & Raymond, E. (2012). Safety and Recommended Phase II Dose (RP2D) of the Selective Oral MEK1/2 Inhibitor Pimasertib (MSC1936369B/AS703026): Results of a Phase I Trial. European Journal of Cancer, 48, 185-186. [604]. https://doi.org/10.1016/S0959-8049(12)72401-2

@article{5da75b8709df48de84d3425faa28e180,

title = "Safety and Recommended Phase II Dose (RP2D) of the Selective Oral MEK1/2 Inhibitor Pimasertib (MSC1936369B/AS703026): Results of a Phase I Trial",

author = "A. Awada and Delord, {J. P.} and N. Houede and C. Lebbe and T. Lesimple and Schellens, {J. H. M.} and S. Rottey and R. Kefford and N. Rejeb and E. Raymond",

year = "2012",

month = nov,

doi = "10.1016/S0959-8049(12)72401-2",

language = "English",

volume = "48",

pages = "185--186",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier",

note = "24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics ; Conference date: 06-11-2012 Through 09-11-2012",

}

Awada, A, Delord, JP, Houede, N, Lebbe, C, Lesimple, T, Schellens, JHM, Rottey, S, Kefford, R, Rejeb, N & Raymond, E 2012, 'Safety and Recommended Phase II Dose (RP2D) of the Selective Oral MEK1/2 Inhibitor Pimasertib (MSC1936369B/AS703026): Results of a Phase I Trial', European Journal of Cancer, vol. 48, 604, pp. 185-186. https://doi.org/10.1016/S0959-8049(12)72401-2

TY - JOUR

T1 - Safety and Recommended Phase II Dose (RP2D) of the Selective Oral MEK1/2 Inhibitor Pimasertib (MSC1936369B/AS703026)

T2 - 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

AU - Awada, A.

AU - Delord, J. P.

AU - Houede, N.

AU - Lebbe, C.

AU - Lesimple, T.

AU - Schellens, J. H. M.

AU - Rottey, S.

AU - Kefford, R.

AU - Rejeb, N.

AU - Raymond, E.

PY - 2012/11

Y1 - 2012/11

U2 - 10.1016/S0959-8049(12)72401-2

DO - 10.1016/S0959-8049(12)72401-2

M3 - Meeting abstract

VL - 48

SP - 185

EP - 186

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

M1 - 604

Y2 - 6 November 2012 through 9 November 2012

ER -